When was Molecular Health founded?

Molecular Health was founded in 2004 and raised its 1st funding round 11 years after it was founded.

Where is Molecular Health located?

Molecular Health is headquartered in Heidelberg, Germany. It is registered at Boston, MA, USA.

Who is the current CEO of Molecular Health?

Friedrich Von Bohlen of Molecular Health. They have also founded 1 company.

Which legal entities is Molecular Health associated with?

Molecular Health is associated with Molecular Health Gmbh and 1 other.

How many employees does Molecular Health have?

As of May 31, 2026, the latest employee count at Molecular Health is 76.

Is Molecular Health a funded company?

Molecular Health is a funded company, having raised a total of $***** in its 1st and only funding round, a PE round on Nov 16, 2015.

When was the latest funding round of Molecular Health?

Molecular Health's latest funding was a $***** PE round on Nov 16, 2015, with participation from 1 investor.

Where does Molecular Health rank among its competitors?

Molecular Health ranks 6th amongst 390 active competitors, of which 73 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was SeqOne, which secured $22.7M in May, 2025.

Who are the top competitors of Molecular Health?

Molecular Health's top competitors include Deep Genomics, Hexagon Bio and BC Platforms. Among them, SeqOne secured the most recent funding round in May, 2025.

Molecular Health - 2026 Company Profile, Team, Funding, Competitors & Financials

Molecular Health is a late stage company based in Heidelberg (Germany), founded in 2004 by Friedrich Von Bohlen. It operates as a Genomic software solutions for healthcare providers. Molecular Health has raised $26.9M in funding from Dievini. The company has 390 active competitors, including 73 funded and 36 that have exited. Its top competitors include companies like Deep Genomics, Hexagon Bio and BC Platforms.

Company Details

Genomic software solutions for healthcare providers. Its proprietary Dataome platform is a SaaS product and is capable of converting both structured and unstructured NGS data into clinically actionable results. The Dataome Knowledgebase contains information for 97k drugs, 54M drug names, 4.6M drug interactions, 85k genomic variants, and 109k clinical trials. Currently, Molecular Health has three products based on its technology. MH Guide Labs converts genetic variant data into a comprehensive tumor profile to enable labs with NGS capabilities. MH Guide Hospitals is an enterprise solution that uses sequencing data to evaluate drug efficacy, drug-drug interactions, and drug-patient compatibility for tailored cancer therapies. MH Effect is a specialized product that predicts drug-drug interactions and drug-induced adverse effects by using patient genomic data.

Website: www.molecularhealth.com/us-en/home/
Social
Email ID: *****@molecularhealth.com
Phone Number: +49 **********
Registered Address: Boston, MA, USA

Key Metrics

Founded Year

2004

Location

Heidelberg, Germany

Stage

Late Stage

Total Funding

$26.9M in 1 round

Latest Funding Round

PE, Nov 16, 2015, $*****

Investors

Dievini & 2 more

Ranked

6^th among 390 active competitors

Employee Count

76 as on May 31, 2026

Similar Companies

Deep Genomics & 537 more

View Molecular Health's full profile

Molecular Health is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Molecular Health, Inc CIN: 27-4242087 , United States, Active	Dec 31, 2003	-	6 (As on Dec 31, 2020)	-
Molecular Health Gmbh CIN: HRB338037 , Germany, Active	Nov 28, 2005	-	115 (As on Dec 31, 2020)

Molecular Health has raised a total funding of $26.9M over 1 round. Its latest funding round was a PE round on Nov 16, 2015 for $*****. 1 investor participated in its latest round. Molecular Health has 2 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Molecular Health:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 16, 2015	7526874	PE	2801986	7671047	7928699	6831290

Access funding benchmarks and valuations. Sign up today!

View details of Molecular Health's funding rounds and investors

The founders of Molecular Health is Friedrich Von Bohlen. Friedrich Von Bohlen is the CEO of Molecular Health.

Here are the details of Molecular Health's key team members:

Friedrich Von Bohlen: Founder & CEO of Molecular Health and founder of 1 other company.

View details of Molecular Health's Founder profiles and Board Members

Molecular Health's employee count trend

Molecular Health has 76 employees as of May 26. Here is Molecular Health's employee count trend over the years:

Employee count trend for Molecular Health

Uncover Molecular Health's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Molecular Health include Deep Genomics, Hexagon Bio and BC Platforms. Here is the list of Top 10 competitors of Molecular Health, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, Khosla Ventures & 16 others	63/100
2nd	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	The Column Group, 8VC & 10 others	63/100
3rd	BC Platforms 1997, Zurich (Switzerland), Series D	Provider of a platforms for genomic data analysis and management	$47.1M	Debiopharm, Tesi & 6 others	58/100
4th	Linus Biotechnology 2020, New York City (United States), Series A	Developer of diagnostic tests for central nervous system and gastrointestinal disorders	$47.6M	GreatPoint Ventures, Bow Capital & 3 others	55/100
5th	SeqOne 2017, Montpellier (France), Series A	Provider of bioinformatics tools for the analysis of genome sequencing data	$48.8M	Omnes Capital, Elaia & 7 others	55/100
6th	Molecular Health 2004, Heidelberg (Germany), Late Stage	Genomic software solutions for healthcare providers	$26.9M	Dievini, The University of Texas at Austin ... & 1 others	56/100
7th	Broken String Biosciences 2020, Cambridge (United Kingdom), Series A	Developer of biopharmaceutical products & cell therapies by using genome sequencing data	$15M	Illumina Ventures, Dieter von Holtzbrinck Ventures ... & 14 others	54/100
8th	Agena Bioscience 2014, San Diego (United States), Acquired	Genetic analysis technology company providing rapid and accurate solutions for research	-	Telegraph Hill Partners, Europa	54/100
9th	Molcure 2013, Tokyo (Japan), Series C	Provider of AI-based platform for drug discovery and design	$11.7M	JAFCO Group, GMO Venture Partners & 7 others	53/100
10th	Intelliseq 2014, Krakow (Poland), Series A	Provider of software for NGS data analysis	$6.45M	YouNick Mint, Vinci & 3 others	52/100